ReviewJournal of cellular and molecular medicine2010
Genes, proteins and complexes: the multifaceted nature of FHL family proteins in diverse tissues.
Review in Journal of cellular and molecular medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.
- FHL5 Controls Vascular Disease-Associated Gene Programs in Smooth Muscle Cells.Circulation research · 2023Pooled it
- Impaired Myogenic Differentiation Is a Shared Feature Across Genetic Myopathies.International journal of molecular sciences · 2026Review
- Article
- Hsa-miR-92b-3p Targeting FHL2 to Enhance Radiosensitivity of Nasopharyngeal Carcinoma.Biochemical genetics · 2025Article
- FHL1 as a prognostic biomarker and therapeutic target in acute promyelocytic leukaemia.Discover oncology · 2025Article
- Role of four and a half LIM domain protein 1 in tumors (Review).Oncology letters · 2025Review
- Unveils key proteins in Xinjiang goat muscle linked to post-mortem meat quality: A TMT-based proteomic analysis.Food chemistry: X · 2024Article
- Fhl1, a new spatially specific protein, regulates vein graft neointimal hyperplasia.Clinical and translational medicine · 2024Article
- FHL2 in arterial medial calcification in chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Article
- Overexpression of FHL1 suppresses papillary thyroid cancer proliferation and progression via inhibiting Wnt/β-catenin pathway.Endocrine · 2024Article
- Low FHL1 expression indicates a good prognosis and drug sensitivity in ovarian cancer.Functional & integrative genomics · 2024Article
- The roles of FHL2 in cancer.Clinical and experimental medicine · 2023Review
- Characterizing the sarcoplasmic proteome of aged pork chops classified by purge loss.Journal of animal science · 2023Article
- Distinct myofibrillar sub-proteomic profiles are associated with the instrumental texture of aged pork loin.Journal of animal science · 2023Article
- Upregulation of the Four and a Half LIM Domains 1 linked with familial venous dysplasia in a familial genetic examination.American journal of translational research · 2023Article
- FHL1 mediates HOXA10 deacetylation via SIRT2 to enhance blastocyst-epithelial adhesion.Cell death discovery · 2022Article
- Three novel FHL1 variants cause a mild phenotype of Emery-Dreifuss muscular dystrophy.Human mutation · 2022Article
- Understanding the molecular basis of cardiomyopathy.American journal of physiology. Heart and circulatory physiology · 2022Review
- Identification of methylation signatures and rules for predicting the severity of SARS-CoV-2 infection with machine learning methods.Frontiers in microbiology · 2022Article
- The Roles of FHL3 in Cancer.Frontiers in oncology · 2022Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Four and a half LIM domain protein 1 (FHL1) is the founding member of the FHL family of proteins characterized by the presence of four and a half highly conserved LIM domains. The LIM domain is a protein-interaction motif and is involved in linking proteins with both the actin cytoskeleton and transcriptional machinery. To date, more than 25 different protein interactions have been identified for full length FHL1 and its spliced variants, and these interactions can be mapped to a variety of functional classes. Because FHL1 is expressed predominantly in skeletal muscle, all of these proteins interactions translate into a multifunctional and integral role for FHL1 in muscle development, structural maintenance, and signalling. Importantly, 27 FHL1 genetic mutations have been identified that result in at least six different X-linked myopathies, with patients often presenting with cardiovascular disease. FHL1 expression is also significantly up-regulated in a variety of cardiac disorders, even at the earliest stages of disease onset. Alternatively, FHL1 expression is suppressed in a variety of cancers, and ectopic FHL1 expression offers potential for some phenotype rescue. This review focuses on recent studies of FHL1 in muscular dystrophies and cardiovascular disease, and provides a comprehensive review of FHL1s multifunctional roles in skeletal muscle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.